Holen Sie sich die Stockscreener-App
0.00
100.00%
-2.38
Handel nachbörslich:
2.34
2.34
+
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SAVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$2.38
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$114.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
0.00
EPS:
-1.38
Netto-Cashflow:
$-82.44M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Firmenname
Cassava Sciences Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
0.00 | 114.97M | 0 | -97.22M | -82.44M | -1.38 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten
Energy Moves: What is Cassava Sciences Inc Equity Warrants book value per share - baoquankhu1.vn
SAVA PE Ratio & Valuation, Is SAVA Overvalued - Intellectia AI
ETF Watch: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Risk Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Cassava Sciences, Inc. Common Stock (FLNA) Competitors - Meyka
Cassava Sciences says DOJ has closed probe into allegations around its Alzheimer’s program - MSN
Cassava Sciences Inc Share PriceShare CFDs - FOREX.com
FOMO Trade: Does Cassava Sciences Inc Equity Warrant offer margin of safety2026 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Trading Recap: Is Cassava Sciences Inc Equity Warrant subject to activist investor interest2026 Sentiment & Daily Stock Trend Watchlist - baoquankhu1.vn
Block Trades: Does Cassava Sciences Inc Equity Warrant have pricing powerMarket Sentiment Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PX91 | US14817C1071 - marketscreener.com
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Filana Therapeutics Inc (FLNA-Q) Profile - The Globe and Mail
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SAVA * | US14817C1071 - marketscreener.com
FLNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cassava Sciences Posts Earnings, Beats Estimates - National Today
Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Filana Therapeutics (NASDAQ: SAVA) pivots to TSC epilepsy amid FDA clinical hold - Stock Titan
Total equity of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Average basic shares outstanding of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Cash Flow – BMV:FLNA - TradingView
Price to book ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Free cash flow per share of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Long term debt to total equity ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Earnings and Revenue – BMV:FLNA - TradingView
Cassava Sciences, Inc. Balance Sheet – BMV:FLNA - TradingView
ETFs Investing in Cassava Sciences, Inc. Stocks - TradingView
FLNA Forecast — Price Target — Prediction for 2027 - TradingView
Filana Therapeutics (NASDAQ: FLNA) pivots to TSC epilepsy amid $91M loss - Stock Titan
Biotech that ditched Alzheimer's drug pivots to epilepsy, slashes R&D 62% - Stock Titan
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Rate Cut: Can Cassava Sciences Inc beat the S P 500Global Markets & Growth Focused Entry Point Reports - baoquankhu1.vn
FLNA Stock Price and Chart — NASDAQ:FLNA - TradingView
Two new option listings and one option delisting on March 11th - TipRanks
Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker - The Globe and Mail
Filana Therapeutics, Inc. will Change its Ticker to FLNA from SAVA - marketscreener.com
Cassava Sciences, Inc. will Change its Ticker to FLNA from SAVA - marketscreener.com
Cassava Sciences, Inc. has Changed its Name to Filana Therapeutics, Inc - marketscreener.com
Investors Purchase Large Volume of Cassava Sciences Call Options (NASDAQ:SAVA) - MarketBeat
Filana Therapeutics (NASDAQ: FLNA) adopts new name and FLNA ticker - Stock Titan
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - cassavasciences.com
Cassava Sciences : SAVA Corp 4Presentation rebrandas of Mar 09 2026 - marketscreener.com
Aug Ideas: Will Cassava Sciences Inc outperform small cap indexesLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Cassava Sciences (NASDAQ:SAVA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program - Stocktwits
Momentum Shift: What dividend growth rate does Cassava Sciences Inc Equity Warrant offerJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
SAVA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cassava Sciences (NASDAQ:SAVA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.80%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):